Boeblingen

• A clinical trial to assess the safety of EXV-802 and EXV-801 and how well they work to reduce agitation symptoms in people with Alzheimer's … Pending
  2024-517388-22-00 10 Agitation in Alzheimer's Disease Dementia
• NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br … Recruiting
  2023-508787-29-00 4 2024-10-10 Triple-negative early breast cancer with low risk for recurrence
• A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated w … Recruiting
  2023-504151-27-00 5 2024-05-09 Psychosis associated with Alzheimer’s Disease
• A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 … Ended recruitment
  2024-512914-16-00 5 2025-09-12 Relapsing-remitting Multiple Sclerosis
• A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended recruitment
  2022-503001-38-01 5 2025-07-08 HR-positive HER-2- negative Breast Cancer
• Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Ended recruitment
  2024-514343-29-00 5 2024-11-19 multiple sclerosis
• A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheim … Ended recruitment
  2023-506183-13-00 4 2024-03-29 Alzheimer’s Disease
• Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine … Ended recruitment
  2022-501172-25-00 5 2024-01-17 Chronic and Episodic Migraine
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc … Ended recruitment
  2022-502611-10-00 5 2020-11-24 Primary Progressive Multiple Sclerosis (PPMS)
• Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended recruitment
  2023-510390-33-00 5 2020-10-23 HER2-negative breast cancer patients with high relapse risk after stan
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk … Ended recruitment
  2024-515769-32-00 5 2019-07-02 HR+/HER2- early breast cancer
• A prospective, multicentre, randomised, double-dummy, double-blind, placebo-controlled 3-way Phase III study to investigate the efficacy and … Halted
  2022-502903-31-00 5 2025-11-05 Patients with ADHD (according to ICD-10 / DSM-5)
• Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy Ended
  2024-513435-24-01 4 2025-06-03 Neuropathic Pain; Distal Sensory Polyneuropathy
• A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in … Ended
  2024-511057-22-00 5 2024-12-04 Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
• A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy a … Ended
  2024-513104-34-00 4 2024-11-25 Major Depressive Disorder
• A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended
  2023-508821-28-00 4 2024-08-14 Migraine
• “A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis” Ended
  2023-503289-22-00 4 2024-07-05 Relapsing Multiple Sclerosis
• A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study Ended
  2024-511560-93-00 5 2022-03-29 Schizophrenia
• A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE) Ended
  2023-506919-18-00 5 2021-05-17 Mild cognitive impairment (MCI) or mild dementia, both of the Alzheime
• Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's … Ended
  2023-504990-19-00 5 2021-04-06 Agitation in Patients With Dementia of the Alzheimer's Type

Showing 1–20 of 20 trials